Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Veterinary Vaccine Import to Russia in 2020

Wednesday, May 19, 2021

In 2020, Russia imported 15.32 billion rubles worth of veterinary vaccines (customs clearance included) from foreign countries except the EEU member states, down 9.4% in monetary terms (rubles) from 2019, because the importers were using up their stocks made in late 2019. The import volume in physical terms amounted to 7.15 million units, or around 43.4 billion dosages. The growth rates are -23.3% in units and -23.1% in dosages.

As for the EEU countries, the import volume amounted to only 0.9 billion rubles (wholesale prices, VAT excluded), or 5.5% of the total import. Besides, Belarus and Kazakhstan mostly imported those products that had previously been imported there. The production made in the EEU countries accounted for 0.8% of the import (see http://rncph.com/news/14_05_2021)

Despite the negative growth rates, vaccines for livestock accounted for 90% of the import volume in monetary terms and for 99.97% of the volume in physical terms, practically unchanged from 2019. At the same time, the growth rates of the import of vaccines for livestock were negative: -11% in rubles and -23% in dosages, while the import of vaccines for pets increased by 4% in monetary but fell slightly in physical terms (-0.3%).

The import of combined vaccines rose by 16% in rubles and went down by 10% in dosages. Only five manufacturing companies imported combined vaccines to Russia in 2020, with Boehringer Ingelheim and Laboratorios Hipra having the highest growth rates: +50% and +44%, respectively. The import of Eurican, vaccines for pets, contributed to the growth rates of Boehringer Ingelheim, and Hiprobovis, vaccine for cattle, helped the growth rates of Laboratorios Hipra.

While the import of live vaccines rose by 10% in monetary terms, it fell by 24% in physical. Three importer are worth mentioning: Elanco (imports increased by 84% in rubles), Czech Biopharm (+78%) and Virbac Group (+77%). Elanco imported the AviPro vaccines, with IBD Xtreme, vaccine for infectious bursal disease, being the most popular of the line. Biopharm and Virbac Group imported only one product each: vaccine for poultry coccidiosis Livacox and Feligen for cats, respectively.

The import of inactivated vaccines dropped by 31% in monetary and by 2% in physical terms. Daesung Microbiological Labs increased their imports 10 times, while importing two vaccines. Their vaccine for porcine circovirus infection Circo Pigvac contributed to the growth rates.

Growth rates of the import of veterinary vaccines to Russia (imports from the EEU countries excluded) between 2015 and 2020, free circulation prices (customs clearance and VAT included)

Share: